SRPT Stock Recent News
SRPT LATEST HEADLINES
Investors searching for high-quality opportunities in the pharmaceutical space should keep a close eye on stocks trading at extremely oversold levels. One of the most popular ways to measure this is through the Relative Strength Index (RSI), a technical momentum indicator that signals when a stock may be due for a rebound.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals ages 3- to less than 8-years-old, who do not have any deletions in exo.
Fundamental investing wisdom tells us to buy stocks with potential when they are trading at a lower valuation. But when a company's prospects look dim, its stock isn't going to be attractive even when trading near its 52-week low.
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the BofA Securities Health Care Conference at the Encore Hotel in Las Vegas, Nev. on Wednesday, May 14, 2025 at 8:40 a.m. P.T./11:40 a.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/eve.
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sarepta Therapeutics, Inc.'s gene therapy SRP-9003 for LGMD 2E/R4 subtype progresses, with potential BLA submission in H2 2025, possibly boosting shareholder value. SRPT rating changed from "Strong Buy" to "Hold" due to uncertainty around sales of DMD drug ELEVIDYS and patient death investigation still underway. Financial risks include potential need for additional funds, possibly diluting shareholders, despite Q1 2025 revenue increase of 70% YoY.
Sarepta Therapeutics Inc. SRPT reported on Tuesday that the first-quarter 2025 loss of $3.42 per share was missing the analyst consensus estimate of losses of 95 cents.